Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 2/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374071 | 0.88 | NAMPT (1.00) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11844425 | 0.88 | NAMPT (1.00) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL146250 | 0.88 | NAMPT (1.00) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL11621172 | 0.87 | NAMPT (0.98) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11847957 | 0.87 | NAMPT (0.98) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11838523 | 0.87 | NAMPT (0.98) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11845343 | 0.87 | NAMPT (0.98) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11838517 | 0.86 | NAMPT (0.95) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11847952 | 0.86 | NAMPT (0.95) | NAMPTMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15308418 | 0.85 | MEN1 (0.78) | NAMPTCNR1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | NAMPT 1938/4885CNR1 174/4885MAPT 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.